secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0001654954-23-002841
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences reports Q4 net loss $3.3M, cash $4.9M; advances TAEUS regulatory submission
--------------------------------------------------------------------------------

- Net loss Q4 2022 $3.3M ($1.04/share) vs Q4 2021 $3.1M ($1.48/share); FY2022 net loss $13.2M ($4.56/share).
- Cash and equivalents $4.9M at Dec 31, 2022; company notes exposure to SVB failure but deposits spread across multiple banks.
- Over 100 TAEUS scans at clinical sites in 2022; interactive guidance tool deployed to improve operator performance.
- Plans to submit De Novo request to FDA for TAEUS liver device; renewed GE HealthCare collaboration through Dec 2024.
- Operating expenses up to $3.3M in Q4 and $13.2M in FY, driven by product development and European commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495423002841/0001654954-23-002841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495423002841/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-002841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer